Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5171MR)

This product GTTS-WQ5171MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5171MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1597MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ10689MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ5477MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ9272MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8778MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ9824MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ4983MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ8526MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW